CINRYZE was the first C1 esterase inhibitor (C1-INH) approved by the FDA for routine prophylaxis of hereditary angioedema (HAE) attacks in adults, adolescents, and pediatric patients (6 years of age and older).1

CINRYZE has been available since 2008 for adolescents and adults. More than 1,000 physicians have prescribed CINRYZE to more than 2,000 patients, resulting in over 709,000 distributed doses.*2

*Figures current as of June 2016

CINRYZE increases plasma levels of C1-inhibitor activity and helps prevent HAE attacks.1

CINRYZE addresses the deficiency or dysfunction of C1-INH. CINRYZE can reduce vascular permeability by preventing the generation of bradykinin.1,3

How CINRYZE® (C1 esterase inhibitor [human]) works1,3,4
How CINRYZE® (C1 esterase inhibitor [human]) works

CINRYZE purification process1

CINRYZE is purified to reduce risk of viral transmission.

  • CINRYZE is derived from natural human plasma collected from U.S. source donors prescreened to rule out infection with human immunodeficiency virus (HIV-1/HIV-2), hepatitis B virus, or hepatitis C virus
  • CINRYZE is purified through a multistep process that includes pasteurization and nanofiltration to minimize a wide range of potential pathogens

Because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, such as viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

You might also be interested in:


  1. CINRYZE® (C1 esterase inhibitor [human]) Prescribing Information. Shire.
  2. Shire Data on File, SHP616-019, December 2017.
  3. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008;359(10):1027–1036.
  4. Kaplan AP, Joseph K. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104(3):193-204.